KaloBios Pharmaceuticals, a US developer of monoclonal antibodies to treat respiratory diseases and cancer, has appointed Harry Lam as Head of Manufacturing.
Lam brings to KaloBios more than 28 years of experience in biopharmaceutical manufacturing, including 17 years at Genentech, where he was ultimately Global Head of Contract Manufacturing Operations, Commercial Drug Substance, for the Roche Group.
'His experience in directing science and technology on a global basis for drug substance manufacturing will be especially pertinent to KaloBios as we continue to advance the development of our patient-targeted antibody therapeutics towards commercialisation,' said David Pritchard, Kalobios' President and Chief Executive.
Lam was most recently Vice President and Head of Manufacturing for Shire Regenerative Medicine. From 1996 to March 2013, he held a variety of increasingly responsible positions at Genentech related to manufacturing operations, manufacturing science and technology and fermentation operations.
In addition to his roles as Global Head of Contract Manufacturing Operations, Commercial Drug Substance (2012–2013), and Senior Director, Global Biologics Drug Substance Manufacturing Science & Technology (2010–2012), during his time at Genentech, Lam led the technology and operations groups in the commissioning, qualification, tech transfer, process validation and licensure of Genentech's bacterial production facility in Singapore (2007–2010).
